Psychopharmacology and Industry, with A/Prof Michael Bowen

In this episode, we welcome Associate Professor Michael Bowen who talks to us about his undergraduate experiences and how they lead him to the impactful work he is doing in the School of Psychology at the University of Sydney developing novel therapeutics. 

Associate Professor Michael Bowen is a neuroscientist and psychopharmacologist at the University of Sydney’s Brain and Mind Centre and School of Psychology. His research is focused on discovering and developing novel therapeutics for substance use disorders and social impairments in brain disorders.

He is the co-founder and Chief Scientific Officer of Kinoxis Therapeutics. Kinoxis was created to commercialize KNX100, a novel molecule that A/Prof Bowen discovered with colleagues at the University of Sydney. KNX100 has considerable potential to treat addiction and other disorders of the brain and mind.

Associate Professor Michael Bowen is the recipient of numerous awards including the Prime Minister’s Prize for New Innovators, the Eureka Prize for Outstanding Early Career Researcher, the NSW Premier’s Prize for Early Career Researcher of the Year, and the International Behavioral Neuroscience Society Early Career Award.

You can find out more about studying psychology at the University of Sydney by following this link.

The School of Psychology is on Twitter here
James Brown is on Twitter here
Sarah A. Walker is on Twitter here